BLUEPRINT MEDICINES CLOSES ON UNDERWRITTEN PO.

 
FREE EXCERPT

Blueprint Medicines Corporation has closed on its underwritten public offering of 4,259,259 shares of its common stock at a public offering price of $81.00 per share, including the exercise in full by the underwriters of their option to purchase additional shares of common stock. Blueprint Medicines estimates net proceeds from the offering will be approximately $325.5 million, after deducting underwriting discounts and commissions and estimated offering expenses.

Goldman Sachs & Co. LLC, Morgan Stanley and Cowen acted as joint book-running managers for the offering. Canaccord Genuity acted as co-manager for the offering.

A registration statement on Form S-3 (File No. 333-216573) relating to these securities has been previously filed with the Securities and Exchange Commission (SEC) and has become effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or...

To continue reading

FREE SIGN UP